Emmanuel Seront

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

Orphanet journal of rare diseases

BMJ case reports

Future science OA

American journal of clinical dermatology

Hopital de Jolimont

Cliniques Universitaires Saint-Luc (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hopital de Jolimont Oct 01 2013

Belgium

MD PhD :: Medical Oncology

Cliniques Universitaires Saint-Luc Oct 01 2009

Belgium

MD PhD :: Medical Oncology

Education History

Cliniques Universitaires Saint-Luc Oct 01 2009

Belgium

PHD :: Medical Oncology

Université catholique de Louvain Institut de Recherche Expérimentale et Clinique Oct 01 2009 - Oct 01 2013

Belgium

PHD :: Fundamental and translational research

Publications

Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe R M Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M Boon
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus. Orphanet journal of rare diseases 19 (1) (2024)
Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe R M Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M Boon
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus. Orphanet journal of rare diseases 19 (1) (2024)
Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe R M Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M Boon
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus. Orphanet journal of rare diseases 19 (1) (2024)
Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe R M Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M Boon
Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus. Orphanet journal of rare diseases 19 (1) (2024)
Julien Pierrard, Emmanuel Seront, Rachel Galot, Idil Gunes Tatar, Jean-Francois Baurain, Dario Di Perri
Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case. Acta clinica Belgica (2023)
Charles Soutif, Thaïs Tison, Isabelle Focant, Emmanuel Seront
Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management. Future science OA 7 (5) (2021)
Aurélie Louvet, Cédric van Marcke, Philippe D'Abadie, Emmanuel Seront
Successful treatment with yttrium-90 microspheres in a metastatic breast cancer patient and sclerosing cholangitis. Future science OA 7 (7) (2021)
Emilie Delchambre, Stéphane Rysselinck, Géraldine Pairet, Caterina Confente, Emmanuel Seront
Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature. Future science OA 7 (6) (2021)
An Van Damme, Emmanuel Seront, Valerie Dekeuleneer, Laurence M Boon, Miikka Vikkula
New and Emerging Targeted Therapies for Vascular Malformations. American journal of clinical dermatology 21 (5) (2021)
Aurore Hendrix, Anne-Emmanuella Yeo, Sarah Lejeune, Emmanuel Seront
Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor. BMJ case reports 13 (6) (2020)
Arnaud Dhenin, Vassiliki Samartzi, Sarah Lejeune, Emmanuel Seront
Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ case reports 12 (6) (2019)
Julien Pierrard, Bénédicte Petit, Sarah Lejeune, Emmanuel Seront
Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab. BMJ case reports 12 (8) (2019)

Emmanuel Seront.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Emmanuel Seront